11/5/2019, 1:05 PM (Source: TeleTrader)
more TeleTrader news

Mylan's revenue jumps 3% to $2.96B in Q3

Mylan N.V. said on Tuesday that its revenue for the third quarter stood at $2.96 billion, up 3% year-over-year. Diluted earnings per share (EPS) amounted to $1.17 in the same period, dropping from $1.25 reported in three months ending September last year.

The pharmaceutical company's net earnings decreased by 7% to reach $604.4 million. On the other hand, diluted net earnings within the United States rose 7% to amount to $189.8 million. Net sales in the US stood at $1.08 billion, surging 8% on an annual basis, while net sales in Europe remained unchanged to reach $1.05 billion. The company's sales rose 3% in the rest of the world to amount to $793.7 million.

"Mylan achieved healthy revenue growth across all segments of our business during the third quarter, supporting solid year-to-date revenue growth as compared with last year on a constant currency basis. We continue to make progress toward a successful deal close with Pfizer's Upjohn business, which we continue to expect will occur in mid-2020," Mylan's chief executive officer Heather Bresch stressed.

Breaking the News / GA